WARSAW, Ind., Jan. 19, 2021 /PRNewswire/ -- Zimmer Biomet
Holdings, Inc. (NYSE and SIX: ZBH), a global leader in
musculoskeletal healthcare, today announced that Ellison
(Ellie) M. Humphrey has been
appointed to the newly created position of Chief Transformation
Officer and will report directly to Bryan
C. Hanson, President and Chief Executive Officer.
Ms. Humphrey joins Zimmer Biomet from global medical technology
company Medtronic, where she held several leadership roles, most
recently serving as Vice President of Enterprise Excellence
and Business Transformation. In her new role at Zimmer Biomet, Ms.
Humphrey will be responsible for connecting key initiatives and
implementing a higher level, more integrated transformation
strategy across the organization.
"Ellie's extensive experience successfully connecting and
overseeing global strategic initiatives for multinational
corporations will prove invaluable to Zimmer Biomet as we continue
to evolve our business to meet the demands of today's ever-changing
healthcare landscape," said Mr. Hanson. "Her unique insights and
deep industry expertise are critical as we continue to drive growth
and work to advance our mission to alleviate pain and improve the
quality of life for people around the world."
Prior to her 11-year tenure at Medtronic, Ms. Humphrey served as
an associate principal at McKinsey & Company, advising
corporate clients on growth, commercial, operational and business
development strategies. She holds a JD from the University of Virginia School of Law, MBA from the
Darden School of Business, and an AB, cum laude, from Harvard College.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in
musculoskeletal healthcare. We design, manufacture and market
orthopedic reconstructive products; sports medicine, biologics,
extremities and trauma products; office-based technologies; spine,
craniomaxillofacial and thoracic products; dental implants; and
related surgical products.
We collaborate with healthcare professionals around the globe to
advance the pace of innovation. Our products and solutions help
treat patients suffering from disorders of, or injuries to, bones,
joints or supporting soft tissues. Together with healthcare
professionals, we help millions of people live better lives.
We have operations in more than 25 countries around the world
and sell products in more than 100 countries. For more information,
visit www.zimmerbiomet.com or follow Zimmer Biomet on
Twitter at www.twitter.com/zimmerbiomet.
Cautionary Statement Regarding Forward-Looking
Statements
This news release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
include, but are not limited to, statements concerning Zimmer
Biomet's expectations, plans, prospects, and product and service
offerings, including new product launches and potential clinical
successes. Such statements are based upon the current beliefs
and expectations of management and are subject to significant
risks, uncertainties and changes in circumstances that could cause
actual outcomes and results to differ materially. For a list
and description of some of such risks and uncertainties, see Zimmer
Biomet's periodic reports filed with the U.S. Securities and
Exchange Commission (SEC). These factors should not be
construed as exhaustive and should be read in conjunction with the
other cautionary statements that are included in Zimmer Biomet's
filings with the SEC. Forward-looking statements speak only
as of the date they are made, and Zimmer Biomet disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. Readers of this news release are cautioned not
to rely on these forward-looking statements, since there can be no
assurance that these forward-looking statements will prove to be
accurate. This cautionary statement is applicable to all
forward-looking statements contained in this news release.
ZBH-Corp
Contacts:
|
|
|
|
Media
|
|
Meredith
Weissman
|
|
(703)
346-3127
|
|
meredith.weissman@zimmerbiomet.com
|
|
|
|
Investors
|
|
Ezgi Yagci
|
Keri
Mattox
|
(617)
549-2443
|
(203)
399-0856
|
ezgi.yagci@zimmerbiomet.com
|
keri.mattox@zimmerbiomet.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zimmer-biomet-appoints-ellison-m-humphrey-as-chief-transformation-officer-301210363.html
SOURCE Zimmer Biomet Holdings, Inc.